news

13 Settembre 2023

IAMA Therapeutics to Present at Sachs Associates 23rd Annual Biotech in Europe Forum

GENOA, Italy, September 13, 2023 — IAMA Therapeutics, a pharmaceutical company focused on the discovery, development, and commercialization of novel medicines for children affected by brain […]
10 Luglio 2023

IAMA Therapeutics Announces Sponsored Research Agreement with The Sapienza University of Rome, Italy

GENOA, Italy, July 10, 2023 — IAMA Therapeutics, a pharmaceutical company focused on the discovery, development, and commercialization of novel medicines for children affected by brain […]
1 Giugno 2023

IAMA Therapeutics to Present at Upcoming BIO International Convention

GENOA, Italy, June 1, 2023 – IAMA Therapeutics, a preclinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel medicines to make a difference in […]
31 Maggio 2023

Business Wire – 31/05/2023

IAMA Therapeutics Announces Addition of Paul Frohna M.D., Ph.D., PharmD, Pierandrea Muglia, M.D. and Elaine Wirrell, M.D., to Scientific Advisory Board
13 Gennaio 2023

Business Wire – 12/01/2023

IAMA Therapeutics and Psychogenics Sign a Preclinical Study Agreement for Dravet Syndrome
26 Luglio 2022

Business Wire – 27/07/22

IAMA Therapeutics Announces Initiation of Preclinical Development Studies in Drug-resistant Epilepsy Under a Service Agreement with Psychogenics
29 Giugno 2022

Business Wire – 29/06/22

IAMA Therapeutics to Present Preclinical Data of Selective NKCC1-Inhibitors at the International Neuroscience Conference FENS Forum 2022
24 Maggio 2022

Business Wire – 24/05/22

IAMA Therapeutics Announces Oral Presentation at the XXVII EFMC International Symposium on Medicinal Chemistry
31 Marzo 2022

Business Wire – 31/03/22

IAMA Therapeutics Announces Formation of Scientific Advisory Board
11 Febbraio 2022

Business Wire – 29/03/22

IAMA Therapeutics Partners with the Italian Institute of Technology to Embark on Landmark Research on Neuroscience Drug Discovery